A study of clinical utilization of glycoproteins as a early diagnostic marker of Alzheimer's disease.

我们先前发现，在阿尔茨海默病(AD)中，三种糖蛋白的糖基化发生了改变。在这项研究中，我们鉴定了所有的糖蛋白，建立了定量每种糖蛋白的糖的方法，并测量了它们的糖基化。与非痴呆对照组(NDC)相比，AD患者血清转铁蛋白和免疫系统相关蛋白改变了多种糖类的含量。阿尔茨海默病患者血清转铁蛋白中的唾液酸在AD早期也有变化，提示转铁蛋白中的唾液酸是诊断AD的有效血清标志物。与非阿尔茨海默病组和非AD痴呆组相比，免疫系统相关蛋白改变了血糖，并与脑脊液淀粉样蛋白β(A-β)相关。该糖蛋白有望成为监测脑内Aβ变化的有效血清标志物。

We previously discovered that the glycosylation of three glycoproteins were altered in Alzheimer's disease (AD). In this study, we identified all glycoproteins, established the methods to quantify the sugars of each glycoproteins and measured glycosylation of them. Identified serum transferrin and immune system associated protein had altered quantities of several kinds of sugar in AD patients compared with non-demented control (NDC) groups. Sialic acid in Alzheimer's serum transferrin also changed in early stage of AD, which suggests the sialic acid of transferrin is an available serum diagnostic marker of AD. Immune system associated protein had altered sugars compared with not only NDC groups but also non-AD dementia groups, and correlated with cerebrospinal fluid amyloid β(Aβ). This glycoprotein is expected to be an efficient serum marker which can monitor the changes of Aβ in the brain.